420 with CNW – New Wisconsin Governor, Democrats Plan to Legalize Marijuana

Wisconsin’s newly elected Democratic leaders are aiming to legalize cannabis in 2027, although they have yet to establish a timeline or agree on the details of the proposed legislation.

The party is set to control both legislative chambers and the governor’s office, the first time in sixteen years. Democrats say Wisconsin is losing tax income as residents shop in neighboring states where cannabis is legal.

Dianne Hesselbein, the incoming Majority Leader of the state senate, said lawmakers had not decided whether legalization would be pursued through a separate bill or folded into the next state budget. Her answer on the approach was that the matter remained undecided.

Meanwhile, Greta Neubauer, the incoming Assembly Speaker, identified the issue as a leading priority for Democrats. She said the caucus was still determining how best to proceed but hoped to pass a measure next year.

Incoming Governor David Crowley made full legalization part of his campaign and has stated that revenue from regulated sales could support priorities including expanded pre-kindergarten programs. He cited Illinois, saying its governor had thanked Wisconsin buyers for generating about $30 million in taxes.

Crowley said cross-border purchases were sending substantial tax revenue elsewhere. He said a legal system would give the state authority to oversee the sector, establish safety rules, and direct proceeds to public safety, education, and health care.

Crowley was also among legislators behind a 2019 proposal covering both medical and recreational marijuana. His spokesperson, Brandon Weathersby, did not state whether Crowley supported Neubauer’s suggested one-year timeline.

Republican leaders have indicated they would consider a proposal once its details are available. Julian Bradley, the incoming Senate Minority Leader, said lawmakers needed to examine the bill’s language before deciding their position.

Democrats have put forward legalization bills for thirteen consecutive years, but the Republican-led Legislature rejected them. Governor Tony Evers also repeatedly proposed legalizing recreational marijuana through his state budgets.

The last Democratic measure, introduced in February, would have permitted people aged 21 and above to possess marijuana for recreational use, while those 18 and above could use it for medical reasons. It also proposed licensing businesses for growth, processing, and sale of marijuana. The bill failed in March.

Wisconsin currently permits only limited medical use of CBD oil. Twenty-four U.S. states and Washington, D.C., have legalized cannabis for both recreational and medical use, while 15 states permit medical use. North Carolina has decriminalized it but retains a ban, and four states prohibit it entirely.

The marijuana movement, including licensed companies like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), will be watching to see whether Wisconsin becomes the next state to end marijuana prohibition.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Investor Pays Record Amount for Ohio Property Housing Marijuana MSO

A commercial property in downtown Columbus, Ohio, has changed hands for $4.1 million, setting an eight-year sale-price record for retail properties in downtown Columbus and highlighting growing investor interest in the state’s expanding marijuana industry.

The 9,900 sq. ft. building, located in the city’s Brewery District, is home to one of Trulieve Cannabis’ dispensaries. An unidentified investor from New York purchased the property, setting the highest retail property sale price in downtown Columbus since 2018.

Records show that the property previously changed ownership for approximately $2.5 million 12 months earlier. Before completing the latest transaction, the seller arranged a decade-long occupancy agreement with Trulieve, providing the cannabis retailer with continued access to the premises.

The agreement follows an absolute triple-net lease structure, commonly known as an NNN arrangement. Under these terms, Trulieve is responsible not only for its rental payments but also for property taxes and other associated operating expenses. Such arrangements can appeal to property investors because they provide a more predictable income stream while transferring several ownership-related costs to the tenant.

Ohio’s cannabis retail sector has continued to grow since recreational marijuana sales began in 2024. The state’s Commerce Department most recently reported 233 licensed dispensaries serving both medical marijuana patients and recreational consumers.

This figure remains considerably below the statewide ceiling of 400 retail outlets established under SB 56. The legislation, which introduced changes to Ohio’s marijuana regulatory framework, became effective in March.

Trulieve operates eight dispensaries across Ohio and has established itself as a significant participant in the state’s marijuana business. The multistate company has increasingly emphasized its position as America’s largest medical marijuana operator.

Its recent regulatory developments include securing registration from the DEA for all its medical cannabis dispensaries. The announcement followed an internal restructuring that separated its recreational marijuana activities from its medical cannabis business.

Chief Executive Officer Kim Rivers discussed the operational changes during the firm’s latest earnings conference. Trulieve also joined the New York Stock Exchange recently after moving its shares to the major U.S. exchange.

The company first established its presence in Ohio through an acquisition three years before the state opened its recreational market.

However, questions remain about whether Trulieve has sought federal registration for dispensaries operating in states with recreational cannabis sales. So far, the DEA has declined applications involving businesses that combine recreational and medical sales under one roof, as well as operators in states with less comprehensive medical marijuana regulations.

For Canadian marijuana firms like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) that have business interests in Ohio, the robust cannabis market of the state presents attractive opportunities once the regulatory environment at the federal level becomes more accommodative.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – LA Times Screening Uncovers Banned Pesticides in Regulated California Marijuana

Fresh laboratory investigations have raised concerns about pesticide contamination in California’s legal marijuana market, with 4 of 49 products examined failing follow-up tests for chemicals subject to pesticide testing restrictions taking effect in April 2028, according to a report published Sunday by the LA Times.

The newspaper also found that 17 additional samples, including cannabis buds, pre-rolled joints and vaping products, contained traces of other potentially harmful pesticides. Although some of these substances face restrictions in other products, California has yet to establish equivalent limits for cannabis products.

The investigation also exposed weaknesses in the state’s efforts to strengthen laboratory supervision. A government reference facility established to independently verify commercial testing results had examined just 35 cannabis samples by the end of August 2026. The facility was introduced amid suspicions that certain testing companies were working with producers to manipulate reported THC potency figures.

California’s marijuana sector generates approximately $3.9 billion annually, making it the largest state-regulated market of its kind in the United States. However, the latest findings have renewed questions about whether authorities have sufficient resources and enforcement measures to protect consumers.

The report follows another troubling incident involving a licensed marijuana operation in Northern California. A worker died at a large cultivation site, and investigators subsequently discovered substantial quantities of hazardous substances during a law enforcement operation.

For its latest investigation, the Times purchased 49 marijuana products through a combination of licensed retail outlets and unregulated sellers. Independent, accredited laboratories were then used to examine the samples. Some of the chemicals identified are not scheduled for inclusion on California’s restricted pesticide register until 2028.

Among the most concerning discoveries was a fungicide detected at concentrations exceeding a hundred times the level that would trigger additional safety scrutiny in tobacco products. The findings have also raised concerns about whether some businesses are adequately following chemical safety requirements.

Four samples failed pesticide testing standards that take effect in April 2028. They included vapes branded Galaxy Sour Diesel and Chico Verde Blood Orange, as well as Wave Rider Super Boof flower and Quiet Kings Chocolatina pre-roll.

California business registration records link two of the flagged brands, Wave Rider and Quiet Kings, to Green Vibe, a Monterey County company authorized to cultivate, manufacture, and distribute marijuana products.

Enforcement figures cited by the Times suggest regulatory action remains limited. Since 2024, the Department of Cannabis Control has reportedly pursued only eight cases against licensed businesses over pesticide-contaminated products.

Furthermore, seven other companies previously identified as users of prohibited agricultural chemicals reportedly continue operating.

The good thing about a legal marijuana market where firms like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are licensed to operate is that products can be independently checked and any shortcomings identified can prompt corrective action. This contrasts with a prohibitionist approach that lets illicit actors corner the market without any oversight being exercised.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Study Suggests Marijuana Effects Could Vary According to Gender

Men who consume marijuana occasionally may experience more intense effects than women with comparable usage patterns, according to new research from UCLA Health. The findings indicate that gender and frequency of consumption could influence how individuals respond to the drug.

Published in the Neuropsychopharmacology Journal, the study involved 44 adults aged 21 to 55. The participants included equal numbers of women and men, who were separated into groups according to how frequently they used marijuana.

During the experiment, each participant attended three sessions and smoked marijuana containing either no THC, a lower THC concentration, or a higher THC concentration. Neither the participants nor those administering the sessions knew which preparation was being used at the time.

Researchers observed notable differences among occasional consumers. Men in this category described feeling more intoxicated, sleepy, and mentally or physically impaired than women who reported similar consumption habits. They were also more likely to experience unwanted reactions, including anxiety. In addition, their heart rates increased considerably following exposure to marijuana containing THC.

Interestingly, blood tests showed that occasional male and female users reached comparable peak THC concentrations.

However, the results were different among participants who consumed marijuana regularly. Women and men in this category showed broadly similar reactions after using the active preparations.

Frequent consumers, irrespective of gender, were also more inclined to enjoy the experience, express interest in using marijuana again and take additional amounts during the experiment.

The observations offer a different perspective from earlier research, some of which indicated that women could be more sensitive to marijuana.

Study author Dr. Ziva Cooper said earlier conclusions were largely informed by human studies and animal experiments that combined findings from separate investigations.

She explained that examining gender alongside consumption frequency, while accounting for hormonal influences, produced a different understanding of the drug’s effects.

To reduce potential hormonal variations, investigators monitored menstrual cycles among female participants. None of the women involved in the research was taking hormonal contraceptives.

Dr. Stephanie Lake, lead author of the study, said both biological sex and previous marijuana exposure should be considered when assessing how people respond to the substance. She noted that studying these factors together could help identify individuals more likely to experience unpleasant, harmful, or positive effects.

The researchers cautioned that their findings should be interpreted carefully. With only 44 participants, the investigation was relatively small, while some observations concerning occasional male consumers came from preliminary analyses requiring further verification.

Another limitation involved the marijuana strength used during testing. The preparations contained THC concentrations of 4 percent and 10 percent, considerably below the levels found in many commercially available products, which frequently exceed 20 percent.

Further research involving larger groups is needed to establish whether women and men develop marijuana tolerance differently and whether these variations influence their susceptibility to cannabis use disorder (CUD).

Until additional research is undertaken using larger populations, the findings of this small study may not offer useful insights to marijuana industry players like Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) that can inform how they advise their customers.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Researchers Uncover Possible Predictor of Marijuana Addiction

The ways people consume marijuana could provide valuable insight into their likelihood of developing problematic use patterns, according to new research. A national study has revealed that individuals who use marijuana in multiple ways have a higher likelihood of developing marijuana use disorder than those who maintain one consumption method.

Although smoking remains the leading consumption method among users, researchers identified a smaller group that regularly combines almost every available option. This category, representing approximately 14% of participants, recorded the highest levels of frequent consumption and addiction-related symptoms.

Cannabis products can be smoked, vaped, eaten, or dabbed. The latter involves inhaling vapor produced by heating highly concentrated marijuana extracts. According to national estimates, around 43.8 million U.S. citizens aged 12 and above had used cannabis within the month preceding the survey.

Scientists examined information from 17,732 adults who reported recent marijuana consumption. Participants were separated into four categories according to their preferred consumption habits.

Primarily smoking accounted for 48% of respondents. Another 21% combined vaping with smoking, while 17% mainly relied on edible products. The remaining participants regularly used multiple consumption methods.

Daily consumption was especially prevalent among those in the last category, with approximately half reporting marijuana use every day. The corresponding figures were 31% among people who vaped and smoked, 28% for those who predominantly smoked, and 13% for those favoring edibles.

Differences were also apparent in assessments of marijuana use disorder. Approximately 67% of participants who used several consumption methods met the diagnostic criteria. The proportion fell to 47% among smokers who also vaped, 36% among those who primarily smoked, and 15% among edible users.

Lead researcher Omar El-Shahawy said asking patients about their preferred consumption methods, rather than simply whether they use marijuana, could help medical professionals recognize individuals who may require further evaluation.

The study, published in Addictive Behaviors, also highlighted demographic differences. Adults aged between 18 and 25 represented substantial portions of the vaping-and-smoking and multiple-method categories. Meanwhile, women and university graduates were more strongly represented among people who mostly consumed edibles.

Researchers additionally noted that cannabis smokers were highly likely to use cigarettes. Researchers warned that inhaling smoke from both substances could increase exposure to potentially harmful substances.

The authors stressed that their findings establish a relationship, not proof that using different cannabis products causes addiction. Since participants reported their own habits, inaccurate responses may also have affected the results.

These findings suggest that using multiple consumption methods may flag a need for further assessment, and recommendations from licensed entities like SNDL Inc. (NASDAQ: SNDL) about the most suitable product type to address one’s needs could help buyers limit unnecessarily hopping from one consumption style to another.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Does Federal Cannabis Legalization Now Stand a Chance After Democrats’ Midterm Wins?

Democrats’ victories in the midterm elections have renewed expectations that Congress could make progress on federal cannabis reform, with the party preparing to take control of both chambers.

The Democratic-led House has previously approved federal legalization proposals twice, with the most recent vote taking place in 2022. Efforts in the Senate, however, have faced greater resistance. Under Senate rules, most legislation requires 60 votes to overcome a filibuster, making it difficult to advance even measures with support from members of both parties, including proposals to improve banking access for marijuana companies.

The debate has also changed since Democrats last held congressional majorities. More states have adopted marijuana legalization policies, while the Trump administration has begun pursuing a narrower change to marijuana classification under the CSA.

Advocates are now urging the incoming Senate majority leader and House speaker to consider broader reform rather than rely solely on administrative changes. Both lawmakers have previously backed legislation to remove marijuana from the CSA. Their proposals have included the 2019 Marijuana Freedom and Opportunity Act and subsequent efforts to establish a regulated national cannabis market.

Democrats could secure up to 56 Senate seats, with 54 already confirmed. Two contests remain unresolved and available results suggest they could be won by Democrats. Passing comprehensive reform would therefore require cooperation from several Republican senators.

NORML’s Morgan Fox said roughly 66 percent of U.S. adults support ending prohibition. He urged Democratic leaders to respond to public opinion by pursuing legislation with bipartisan backing.

Fox also cautioned that federal rescheduling remains incomplete. Although medical cannabis has been moved to Schedule 3, broader changes covering recreational cannabis remain uncertain because of ongoing proceedings involving the DEA.

Drug Policy Alliance representative Cat Packer similarly argued that rescheduling alone would not address the consequences of federal criminalization. She called for legislation protecting individuals, improving public health safeguards, and creating a regulatory framework covering marijuana and hemp.

Meanwhile, National Cannabis Industry Association board chair Adam Rosenberg said Democratic control could help advance banking access, tax changes, and clearer rules for state-licensed businesses. He noted that the industry generates over $29 billion annually and supports over 400,000 workers.

Despite growing industry engagement, Republican congressional leaders have generally resisted legalization proposals. Political contributions from cannabis executives to Democratic fundraising groups have also drawn attention, alongside spending by a pro-Trump political committee supporting Republican lawmakers, including some who have opposed cannabis reform.

For firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) that have for long participated in efforts to reform marijuana laws at state level, the excitement about Democratic control of Congress may be premature for the industry since Trump holds veto powers and any bill passed could be stopped in its tracks by opposition from the president.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Organigram to Merge with Aurora Cannabis, Locking Out Curaleaf

Organigram and Aurora Cannabis have unveiled an agreement to bring their businesses together, marking a significant development in the Canadian industry following months of pressure from U.S.-based rival Curaleaf, which had been pursuing an unsolicited acquisition of Aurora.

The proposed combination will unite the companies’ operations across Australia, Canada, and Europe, creating a broader international business with complementary strengths. Organigram brings an established recreational cannabis business in Canada, extensive production infrastructure, research, and development capabilities, and medical marijuana operations in Europe.

Aurora contributes its international medical marijuana business, established overseas distribution channels, and manufacturing facilities certified under European Union Good Manufacturing Practice (EU-GMP) standards.

The merged entity will continue to have financial backing from BT DE Investments, which is part of the British American Tobacco group and serves as a key investor in Organigram.

Under the agreement, Organigram will acquire Aurora at a share value of $5.59. The proposed purchase places Aurora’s value at roughly $401 million.

According to the companies, the offer represents a 93 percent increase over Aurora’s unaffected closing stock price on the Toronto Stock Exchange on Aug. 10. It also exceeds the value attached to Curaleaf’s outstanding hostile proposal by approximately 21%.

Organigram chief executive James Yamanaka described the agreement as an important milestone in the company’s ambitions to establish a financially disciplined international marijuana business. He said combining the two companies would create greater scale, diversify operations, and strengthen their ability to respond to rising demand in international markets.

Yamanaka also highlighted the potential benefits of bringing together their expertise, production capabilities, financial resources, and existing commercial networks, with profitability and sustainable expansion among the priorities.

Aurora chief executive Miguel Martin said the arrangement would support the company’s overseas expansion plans by improving commercial operations and extending its international infrastructure.

He added that the agreement followed an extensive strategic assessment and offered Aurora investors an attractive financial outcome. Shareholders would also have flexibility in deciding how to receive consideration, alongside an opportunity to retain exposure to the future performance of the combined business.

The proposed transaction follows an increasingly contentious dispute over Aurora’s ownership. Last week, Curaleaf addressed a decision by Alberta’s Securities Commission concerning Aurora’s ATM share issuance program.

Curaleaf chairman and CEO Boris Jordan argued that the regulatory decision did not resolve the concerns his company had raised about Aurora’s handling of the takeover process.

Jordan questioned why Aurora had issued shares through its ATM program below Curaleaf’s initial offer price after being informed that a proposal was forthcoming. He also challenged the company’s assessment of Curaleaf’s revised offer, which he said represented an 86% premium but had still been characterized as insufficient.

He further criticized Aurora’s refusal to provide Curaleaf with access to customary due diligence while other parties were permitted to proceed, arguing that shareholders should have the opportunity to assess an informed process before deciding on the company’s future.

Other medical cannabis firms in the country, such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED), will be analyzing how the merger could impact the overall industry’s dynamics within Canada.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Study Links Marijuana Use to Heightened Heart Disease Risk

Cannabis consumption may be associated with an increased likelihood of cardiovascular disease, particularly stroke, according to a recent preliminary study.

The findings suggest that the potential health risks are not limited to smoking marijuana. Researchers identified similar associations among people who consumed cannabis through different methods, including vaping and edible products.

The research comes amid a rise in cannabis consumption across the U.S. Approximately one in six American adults reported using marijuana during the previous month in 2024. This compares with one in ten in 2020, representing a 51 percent increase.

Earlier studies have also connected cannabis consumption with unfavorable cardiovascular outcomes. Some suggested that individuals using the substance more frequently faced greater health risks. However, evidence from previous investigations has not always been consistent, prompting researchers to investigate the relationship further.

For the latest analysis, investigators examined survey responses from 442,906 American adults collected through the Behavioral Risk Factor Surveillance System from 2020 to 2024. Participants answered questions about their cannabis habits and whether medical professionals had previously diagnosed them with cardiovascular conditions, including heart attacks, coronary disease, and strokes.

The results revealed notable differences across consumption groups. Compared with individuals who had not recently used cannabis, respondents reporting consumption on one to five days monthly had 23 percent greater odds of reporting a cardiovascular disease history. Those using it between 16 and 30 days in a month recorded 21 percent higher odds.

Stroke showed the strongest association. Participants reporting occasional consumption had 40 percent higher odds of having experienced a stroke, while frequent users recorded a 25 percent increase. However, researchers found no statistically meaningful relationship between heart attacks and monthly consumption frequency.

The findings differed from expectations because cardiovascular risk did not consistently increase alongside more frequent consumption. Both occasional and frequent users demonstrated elevated odds of cardiovascular disease.

The analysis included adjustments for several potential contributing factors, such as age, income, education, tobacco consumption, alcohol intake, obesity, diabetes, physical activity, and kidney disease.

Nevertheless, the findings have some limitations. Since the research examined reported health conditions and cannabis habits at a particular point rather than tracking changes over time, it cannot establish that cannabis directly causes cardiovascular disease. Information was also self-reported, leaving room for inaccurate recollections.

Additionally, researchers lacked details about product strength and quantities consumed. Some participants may also have stopped using cannabis following a diagnosis.

Marijuana businesses like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) will be hoping that more rigorous studies are conducted to confirm or rule out the findings of this preliminary study so that consumers can get appropriate advice when they visit licensed outlets.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – Marijuana Firms Uncertain About Tax amid Federal Guidance Lacuna

Missouri’s cannabis industry is facing a major tax question after federal officials took steps this year to ease restrictions on medical marijuana.

The change could allow qualifying cannabis companies to claim federal deductions for routine business costs such as rent, wages, and other operating expenses. For years, those deductions have largely been blocked by Section 280E, which applies to businesses dealing in substances prohibited under federal law.

The potential savings are significant. Cannabis companies can face effective federal tax rates approaching 80%, compared with the 21% corporate rate applied to many other businesses.

Yet Missouri operators are still waiting for clear instructions on how the new rules will apply, particularly because the state permits companies to serve both recreational consumers and medical patients.

That issue came up during a recent discussion by the state cannabis regulators. Representatives of the state Cannabis Trade Association stated that businesses need direction from the IRS before they can confidently determine which expenses qualify.

Andrew Mullins, the association’s executive director, described cannabis as one of Missouri’s most heavily regulated and taxed industries.

Under the federal action announced in April, marijuana covered by state medical programs was moved into Schedule 3 of the Controlled Substances Act. Recreational cannabis, however, remained in Schedule 1.

That distinction creates complications for Missouri companies operating under comprehensive licenses, which permit both types of sales. The state does not require businesses to maintain separate cultivation systems for medical and adult-use products.

Amy Moore, who leads Missouri’s marijuana regulatory division, said the federal approach appears to distinguish medical marijuana in a way that does not neatly match Missouri’s licensing structure.

Drew Lammert, who chairs the trade group’s government relations committee, said companies may ultimately need to develop their own methods for assigning shared expenses. His cannabis company gets roughly 10% of its revenue from medical sales.

One possible method would be to use the proportion of dispensary purchases made by medical customers when allocating costs incurred by cultivators and manufacturers. Another proposal discussed by regulators would rely on the medical portion of sales statewide.

Neither approach has been endorsed by federal tax authorities.

The IRS and the Department of Treasury have identified Section 280E guidelines as a priority for the next fiscal year, but that list contains over 100 other projects.

Tax adviser Kevin Jednachowski has urged operators to prepare for several possible outcomes rather than assume relief will arrive on schedule. He advises businesses to estimate their potential tax bills under different outcomes, from receiving no tax relief to claiming the largest deductions they can reasonably justify.

For companies, the difference could affect cash flow, expansion plans, payroll, and supplier arrangements. Detailed records may also become critical. Businesses can begin documenting inventory, facility expenses, employee time, and other shared costs now, giving them evidence to support whatever allocation method they eventually use.

This tax guidance lacuna isn’t only affecting businesses in Missouri. Even firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) in other legal markets could also be awaiting guidance from the IRS.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW – California Social Equity Marijuana Businesses More Active Than Non-Equity Ones, Data Shows

A new review of California’s marijuana licensing data challenges the notion that retailers operating under social equity programs are more likely to lose their licenses than other cannabis retail businesses.

Capitol Compliance Management, a consulting firm based in Sacramento, examined 1,653 cannabis retail licenses listed in the California Department of Cannabis Control’s registry. The dataset included 281 licenses identified as equity retailers, making up roughly 17 percent of all storefront licenses reviewed.

According to data collected on Sep. 25, about 81 percent of the equity-designated licenses were listed as active. That compared with an active rate of approximately 76 percent among retailers without the designation.

The firm also accounted for differences in the age of the licenses. Since equity permits tended to have been issued more recently, researchers compared retailers that received licenses during the same calendar year. From 2019 to 2022, equity retailers recorded higher active-license rates than their non-equity counterparts. The pattern shifted in later years, with equity retailers posting a lower rate in 2023, matching other retailers in 2024 and falling behind in 2025.

The gap was most pronounced among 2019 licenses. The year saw the granting of 52 equity licenses, with 41 remaining active, resulting in a retention rate of nearly 79 percent. Non-equity retailers posted a lower rate of about 66 percent, with 559 licenses issued and roughly two-thirds remaining active.

Los Angeles County accounted for the largest share of equity licenses in the statewide dataset, with 156, or over 50% of the total. San Francisco has 19, while Sacramento County has 26. The figures cover licenses regardless of whether they were active and therefore should not be interpreted as a count of currently operating cannabis stores.

Kevin McCarty, the report’s author and head of compliance and licensing at the consulting firm, said the continued presence of older equity licenses was particularly notable. He cautioned that an active license alone can’t show whether a retailer is financially stable or profitable but argued that the figures provide grounds for reassessing assumptions about the durability of equity businesses.

The analysis comes with an important limitation. License status doesn’t reveal a retailer’s revenue, profitability, outstanding liabilities, or changes in ownership. It therefore offers only one measure of business continuity rather than a complete picture of performance.

The report also discloses that McCarty is an owner of two equity-designated licenses.

Data of this nature captured in the analysis suggests that the marijuana ecosystem is active and related businesses operating in the same way as Innovative Industrial Properties Inc. (NYSE: IIPR) have a fairly stable client base to serve in California.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN